查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1588299

骨系統疾病市場規模、佔有率、趨勢分析報告：按類型、治療、症狀、地區和細分市場預測，2025-2030

Skeletal Dysplasia Market Size, Share & Trends Analysis Report By Type (Achondroplasia, X-linked Hypophosphatemia, Hypophosphatasia), By Treatment, By Symptom, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

骨系統疾病市場成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球骨系統疾病市場規模將達到38.5億美元，2025年至2030年複合年成長率為2.0%。

該疾病的盛行率不斷上升，尤其是在兒童中，以及孤兒藥的日益採用可能有助於市場的擴張。

在各種疾病中，軟骨發育不全是最常見的疾病。根據美國國家人類基因組研究所 2016 年發布的估計，每 15,000 至 40,000 人中就有 1 人患有軟骨發育不全。目前，還沒有專門針對軟骨發育不全的核准治療方法，但有五種治療方法正在臨床開發中。

這種疾病引起的遺傳異常包括 FGFR3 基因的自然突變。 BioMarin 的 Vosoritide 以抑制 FGFR3途徑為目標，是治療軟骨發育不全的First-in-Class藥物。該藥物正處於III期臨床試驗，預計2024年進入市場。 Clementia（易卜生集團）和 Regeneron 是針對多發性骨軟骨瘤和進行性肌肉骨化症(FOP) 等疾病的其他市場參與者。這些管道藥物在預測期內獲得孤兒藥核准預計將進一步推動骨病市場的成長。

藥物根據疾病的遺傳原因而有所不同，核准治療方法XLH 和低磷酸酯酶症等疾病的藥物包括 Ultragenics Pharmaceuticals 的 Crysvita 和 Alexion Pharmaceuticals 的 Strensiq。 Crysvita 於 2018 年獲得 FDA核准，而 Strensiq 於 2015 年獲得核准。 Strensiq 的銷售額從 2015 年的 1,200 萬美元增至 2018 年的 4.751 億美元。這些孤兒藥的使用量不斷增加是市場成長的訊號。

骨系統疾病市場報告亮點

  • 低磷酸酯酶症 (HPP) 佔據市場主導地位，2024 年佔據最大銷售佔有率，達到 48.5%。
  • 藥物療法引領市場，2024 年佔最大銷售佔有率，達 48.5%。
  • 骨骼畸形，包括副甲狀腺疾病、荷爾蒙療法以及脊椎和四肢截骨術，佔據市場主導地位，2024年佔最大銷售佔有率，為20.9%。
  • 歐洲骨系統疾病市場主導全球市場，2024年佔最大收益佔有率為39.4%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章骨系統疾病市場的變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章骨系統疾病市場：依疾病類型進行的商業分析

  • 2024 年和 2030 年按疾病類型市場佔有率
  • 故障類型細分儀表板
  • 2018-2030 年按殘障類型分類的市場規模及預測與趨勢分析
  • X連鎖低血磷症（XLH）
  • 低磷酸酯酶症（HPP）
  • 軟骨發育不全
  • 進行性肌肉骨化症(FOP)
  • 多發性骨軟骨瘤 (MO)

第5章骨系統疾病市場：依治療進行業務分析

  • 2024年及2030年治療市場佔有率
  • 治療細分儀表板
  • 2018-2030年市場規模及預測與趨勢分析、處理
  • 藥品
  • 外科手術

第6章骨系統疾病市場：依症狀進行業務分析

  • 2024 年及 2030 年症狀市場佔有率
  • 症狀細分儀表板
  • 2018-2030 年市場規模、預測與趨勢分析（按症狀）
  • 骨骼變形
  • 牙齒畸形
  • 其他

第7章骨系統疾病市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
    • 俄羅斯
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 香港
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介
    • BioMarin
    • Amgen Inc.
    • Merck KGaA
    • Regeneron
    • Alexion Pharmaceuticals, Inc.
    • Clementia（Ipsen Group）.
    • AstraZeneca plc.
    • Biomarin Pharmaceuticals Inc.
    • Cipla Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: GVR-3-68038-954-8

Skeletal Dysplasia Market Growth & Trends:

The global skeletal dysplasia market size is expected to reach USD 3.85 billion by 2030, registering a CAGR of 2.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of this condition, especially in children, and growing adoption of orphan drugs are likely to contribute to the expansion of the market.

Among different disorders, achondroplasia is the most common condition. According to estimates published by the National Human Genome Research Institute in 2016, achondroplasia occurs in 1 in 15,000-40,000 live births. Although there are no current therapies approved specifically for achondroplasia, there are five therapies under clinical development.

Genetic defects attributable to the disorder include spontaneous mutations in the FGFR3 gene. Vosoritide by BioMarin targets inhibition of the FGFR3 pathway and presents a first-in-class drug for achondroplasia. The drug is in phase III clinical trial and is expected to enter the market in 2024. Clementia (Ipsen Group) and Regeneron are other market players targeting disorders such as multiple osteochondromas and fibrodysplasia ossificans progressiva (FOP). Approval of these pipeline therapies with orphan drug status during the forecast period will further support skeletal dysplasia market growth.

The medicines vary depending on the genetic cause of the disorder and only a handful of the disorders, such as XLH and hypophosphatasia, have approved curative therapies, including Ultragenyx Pharmaceuticals' Crysvita and Alexion Pharmaceuticals' Strensiq, respectively. Crysvita received FDA approval in 2018 whereas Strensiq received approval in 2015. The sales of Strensiq increased from USD 12.0 million in 2015 to USD 475.1 million in 2018. Higher uptake of these orphan drugs signal growth of the market.

Skeletal Dysplasia Market Report Highlights:

  • Hypophosphatasia (HPP) dominated the market and accounted for the largest revenue share of 48.5% in 2024 attributed to the increasing awareness and improved diagnostic capabilities, leading to more frequent diagnoses of this rare genetic disorder.
  • Medications led the market and accounted for the largest revenue share of 48.5% in 2024 attributed to the advancements in drug development and increased awareness of skeletal dysplasias.
  • Skeletal deformities, including parathyroid disorders, growth hormone therapies, and spinal and limb osteotomies, dominated the market and accounted for the largest revenue share of 20.9% in 2024.
  • Europe skeletal dysplasia market dominated the global market and accounted for the largest revenue share of 39.4% in 2024 attributed to heightened awareness and improved diagnostic capabilities.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disorder Type
    • 1.2.2. Treatment
    • 1.2.3. Symptoms
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Skeletal Dysplasia Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Skeletal Dysplasia Market: Disorder Type Business Analysis

  • 4.1. Disorder Type Market Share, 2024 & 2030
  • 4.2. Disorder Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disorder Type, 2018 to 2030 (USD Million)
  • 4.4. X-linked Hypophosphatemia (XLH)
    • 4.4.1. X-linked Hypophosphatemia (XLH) Market, 2018 - 2030 (USD Million)
  • 4.5. Hypophosphatasia (HPP)
    • 4.5.1. Hypophosphatasia (HPP) Market, 2018 - 2030 (USD Million)
  • 4.6. Achondroplasia
    • 4.6.1. Achondroplasia Market, 2018 - 2030 (USD Million)
  • 4.7. Fibrodysplasia Ossificans Progressive (FOP)
    • 4.7.1. Fibrodysplasia Ossificans Progressive (FOP) Market, 2018 - 2030 (USD Million)
  • 4.8. Multiple Osteochondromas (MO)
    • 4.8.1. Multiple Osteochondromas (MO) Market, 2018 - 2030 (USD Million)

Chapter 5. Skeletal Dysplasia Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2030
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 5.4. Medication
    • 5.4.1. Medication Market, 2018 - 2030 (USD Million)
  • 5.5. Surgery
    • 5.5.1. Surgery Market, 2018 - 2030 (USD Million)

Chapter 6. Skeletal Dysplasia Market: Symptoms Business Analysis

  • 6.1. Symptoms Market Share, 2024 & 2030
  • 6.2. Symptoms Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Symptoms, 2018 to 2030 (USD Million)
  • 6.4. Skeletal Deformities
    • 6.4.1. Skeletal Deformities Market, 2018 - 2030 (USD Million)
  • 6.5. Dental Deformities
    • 6.5.1. Dental Deformities Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Skeletal Dysplasia Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Skeletal Dysplasia Market Estimates and Forecastsasts, 2018 - 2030 (USD Million)
    • 7.5.10. Russia
      • 7.5.10.1. Key Country Dynamics
      • 7.5.10.2. Regulatory Framework
      • 7.5.10.3. Competitive Insights
      • 7.5.10.4. Russia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Hong Kong
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Hong Kong Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.8. Thailand
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Regulatory Framework
      • 7.6.8.3. Competitive Insights
      • 7.6.8.4. Thailand Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. BioMarin
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Amgen Inc.
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck KGaA
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Regeneron
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Alexion Pharmaceuticals, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Clementia (Ipsen Group).
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. AstraZeneca plc.
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Biomarin Pharmaceuticals Inc.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Cipla Ltd.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Eli Lilly and Company
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. F. Hoffmann-La Roche AG.
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Pfizer, Inc.
      • 8.5.12.1. Company Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Teva Pharmaceutical Industries Ltd.
      • 8.5.13.1. Company Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Skeletal Dysplasia Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 5 Global Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 6 Global Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 7 North America Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 9 North America Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 10 North America Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 11 U.S Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 12 U.S Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 13 U.S Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 14 Canada Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 16 Canada Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 17 Mexico Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 19 Mexico Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 20 Europe Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 23 Europe Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 24 UK Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 25 UK Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 26 UK Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 27 Germany Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 29 Germany Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 30 France Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 31 France Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 32 France Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 33 Italy Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 34 Italy Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 35 Italy Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 36 Spain Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 38 Spain Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 39 Norway Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 40 Norway Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 41 Norway Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 42 Denmark Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 43 Denmark Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 44 Denmark Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 45 Sweden Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 46 Sweden Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 47 Sweden Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 52 Japan Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 53 Japan Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 54 Japan Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 55 China Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 56 China Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 57 China Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 58 India Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 59 India Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 60 India Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 61 Australia Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 62 Australia Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 63 Australia Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 64 South Korea Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 65 South Korea Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 66 South Korea Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 67 Thailand Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 68 Thailand Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 69 Thailand Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 70 Latin America Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 72 Latin America Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 73 Latin America Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 74 Brazil Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 75 Brazil Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 76 Brazil Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 77 Argentina Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 78 Argentina Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 79 Argentina Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 84 South Africa Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 85 South Africa Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 86 South Africa Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 90 UAE Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 91 UAE Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 92 UAE Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Skeletal Dysplasia market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook
  • Fig. 10 Segment outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Skeletal dysplasia market dynamics
  • Fig. 13 Skeletal dysplasia market: Porter's five forces analysis
  • Fig. 14 Skeletal dysplasia market: PESTLE analysis
  • Fig. 15 Skeletal dysplasia market: Disorder Type segment dashboard
  • Fig. 16 Skeletal dysplasia market: Disorder Type market share analysis, 2024 & 2030
  • Fig. 17 X-linked hypophosphatemia (XLH) market, 2018 - 2030 (USD Million)
  • Fig. 18 Hypophosphatasia (HPP) market, 2018 - 2030 (USD Million)
  • Fig. 19 Achondroplasia market, 2018 - 2030 (USD Million)
  • Fig. 20 Fibrodysplasia ossificans progressive (FOP) market, 2018 - 2030 (USD Million)
  • Fig. 21 Multiple osteochondromas (MO) market, 2018 - 2030 (USD Million)
  • Fig. 22 Skeletal dysplasia market: Treatment segment dashboard
  • Fig. 23 Skeletal dysplasia market: Treatment market share analysis, 2024 & 2030
  • Fig. 24 Medication market, 2018 - 2030 (USD Million)
  • Fig. 25 Surgery market, 2018 - 2030 (USD Million)
  • Fig. 26 Skeletal dysplasia market: Symptoms segment dashboard
  • Fig. 27 Skeletal dysplasia market: Symptoms market share analysis, 2024 & 2030
  • Fig. 28 Skeletal deformities market, 2018 - 2030 (USD Million)
  • Fig. 29 Dental deformities laboratories market, 2018 - 2030 (USD Million)
  • Fig. 30 Others market, 2018 - 2030 (USD Million)
  • Fig. 31 Skeletal dysplasia market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico country dynamics
  • Fig. 40 Mexico skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 41 Europe skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 42 UK country dynamics
  • Fig. 43 UK skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 44 Germany country dynamics
  • Fig. 45 Germany skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 46 France country dynamics
  • Fig. 47 France skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 48 Italy country dynamics
  • Fig. 49 Italy skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain country dynamics
  • Fig. 51 Spain skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 52 Norway country dynamics
  • Fig. 53 Norway skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark country dynamics
  • Fig. 57 Denmark skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 59 Japan country dynamics
  • Fig. 60 Japan skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 61 China country dynamics
  • Fig. 62 China skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 63 India country dynamics
  • Fig. 64 India skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea country dynamics
  • Fig. 68 South Korea skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 69 Thailand country dynamics
  • Fig. 70 Thailand skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 71 Latin skeletal dysplasia Dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 72 Brazil country dynamics
  • Fig. 73 Brazil skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 76 MEA Skeletal Dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 83 Kuwait Key country dynamics
  • Fig. 84 Kuwait skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework